Stoke Therapeutics earnings: Investors brace for revenue test

Stoke Therapeutics (STOK) reports Q3 earnings, with analysts expecting a $0.93 loss per share on $8.21M revenue, down 12% sequentially. The company is developing RNA medicines, with key updates on zorevunersen for Dravet syndrome and STK-002 for optic atrophy. All 14 analysts rate it a Strong Buy with a $46.46 target, implying 75.9% upside. Investors will focus on revenue trends and clinical progress.

Original reporting
Published Oct 29, 2026, 1:38 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 1:51 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$STOK
Bearish
high confidence
Mentioned
$STOK
Relevance
6/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$STOKBearishMed
01

Why it matters

The guidance suggests a slowdown, which may trigger a re‑rating by analysts and affect the stock's valuation multiples.

02

Market read

The guidance release is the primary catalyst for short‑term price movement in STOK.

03

What to watch

Potential upside from upcoming Phase 3 readout and NDA filing could offset short‑term revenue dip.

Relevance 6/10Novelty 7/10Timing: pre‑market before earnings release

Background

Stoke Therapeutics is a pre‑commercial biotech focused on RNA medicines, recently noted for surprising revenue performance in Q2.

Company-level read

Ticker impact

$STOKBearishHigh confidence
Context

The article provides the first public forecast of Stoke Therapeutics' Q3 earnings, including expected loss per share and revenue figures.

Expected impact

likely downward pressure as investors reassess revenue momentum

Evidence & confidence

Guidance is below prior quarter and below expectations for growth, prompting sell‑side caution.

Market effects

Highlights challenges for the broader RNA therapeutics sector in sustaining revenue growth.

Limited to U.S. biotech investors; no broader regional effect.

Minimal global impact beyond niche biotech community.

Counterpoint

Some investors may view the flat loss as a sign of disciplined cost control and maintain a bullish stance.

Key entities

  • Stoke Therapeutics

    RNA medicine developer reporting Q3 earnings guidance.

Related articles

$NOCMed

ULA’s Latest Launch Failure Spells Trouble for Space Force

United Launch Alliance's (ULA) Vulcan Centaur rocket failed during a Nov. 15 launch, destroying 40 Amazon satellites and tightening Space Force launch capacity. The issue was attributed to inadequate fuel supply to the BE-4 engines, built by Blue Origin. ULA faces further investigation, while SpaceX's successful Starship test cements its dominance.

$STOKMed

Stoke Therapeutics Q3 Earnings Call Highlights

Stoke Therapeutics (STOK) discussed Q3 earnings, highlighting plans for zorevunersen's NDA submission in 2027. The FDA supports a multicomponent endpoint for cognition/behavior. Stoke estimates 38,000 Dravet syndrome patients in key markets. STK-002 for ADOA is in Phase I trials. Q3 net loss was $73.6M, with $358.8M cash. Stoke expects funding into early 2028.

$STOKMed

Stoke Q3 2026 slides: EMPEROR trial advances with zero dropouts

Stoke Therapeutics (STOK) reported Q3 2026 progress, highlighting zero dropouts in its EMPEROR Phase 3 trial for zorevunersen in Dravet syndrome. The company beat revenue estimates but reported a wider-than-expected loss. Stoke has $358.8M in cash, enough to fund operations into early 2028. The trial enrolled 162 patients, exceeding the target, with strong patient retention and statistical significance in endpoints. The FDA has accepted the study's multicomponent approach for regulatory filing.

$STOKMed

Stoke Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Updates

Stoke Therapeutics, Inc. (STOK) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX 99.1 Stoke Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Updates –Phase 3 EMPEROR study of zorevunersen, an investigational medicine for Dravet syndrome: ~110 patients through Week 28 primary endpoint, ~20 patients through Week 52 and all co

$STOKMedAI 8/10

About 110 patients reached the seizure-measurement point in a Dravet drug trial

Stoke Therapeutics reported progress in its Phase 3 EMPEROR study for zorevunersen, an investigational drug for Dravet syndrome, with 110 patients reaching the Week 28 primary endpoint. The company plans to submit data to the FDA in the first half of 2027 and complete the NDA submission in the second half. Additionally, the Phase 1 OSPREY study for STK-002, targeting ADOA, is ongoing with initial data expected in H1 2027.